Acadia Pharmaceuticals Inc


ACAD

Price

18.79


Change

-1.15


High

20


Low

18.49


Avg Volume

1,191,925


PE Ratio

-15.66


52 Week High

57.34


52 Week Low

15.68



Profile

Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Sorrento Valley, San Diego, California. Nuplazid, a drug developed by Acadia in the late 1990s, "was designed to stimulate a subset of the brain’s serotonin receptors, or the proteins that govern memory, cognition and learning." On April 29, 2016, the FDA approved Acadia's drug, Nuplazid, for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. Nuplazid is the trade name for Acadia's proprietary molecule, pimavanserin, a selective serotonin inverse agonist preferentially targeting 5-HT2a receptors. Acadia had partnered with Biovail in the late-stage clinical testing of the drug, which showed trial failures as of 2009.


Top Streaming News


Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.

Data provided by IEX Cloud

About

Copyright © 2020 Finaza.IO. All Rights Reserved.